Amgen drug tied to death risks in tests as transfusion substitute

A new study of Amgen's Aranesp said it was linked to an almost 45% increase in death in trials testing it for reducing the need for blood transfusions in anemic cancer patients. Aranesp already is approved for treating the anemia itself, a side effect of chemotherapy, and an FDA advisory panel plans to meet in May to consider the entire class of erythropoiesis-stimulating agents.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC